USA flag logo/image

An Official Website of the United States Government

Betahistine: Novel Therapeutic in Attention Deficit Hyperactivity Disorder

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
94008
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
MH082461
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
P2D, INC.
10101 Alliance Rd CINCINNATI, OH 45242-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Betahistine: Novel Therapeutic in Attention Deficit Hyperactivity Disorder
Agency: HHS
Contract: 1R43MH082461-01
Award Amount: $469,495.00
 

Abstract:

DESCRIPTION (provided by applicant): Satiety Solutions, is developing a novel histamine agonist, betahistine, as a treatment for attention-deficit, hyperactivity disorder (ADHD). Betahistine is a histamine activator which has been found to improve vigilanc e in normal volunteers. Conventionally, betahistine has been used world-wide at low dose to treat Meniere's Syndrome (vertigo) for over thirty-five years. Exploratory dose-ranging in normal volunteers suggests that higher doses of betahistine are required to enhance vigilance. The immediate goal of this Phase I SBIR is to determine safety, tolerability, and pharmacokinetics of betahistine single-doses gt 48 mg and to determine a dose-response for improving attention and impulsivity in young adults with ADHD . Specific Aim 1: Evaluate the safety and tolerability of betahistine hydrochloride in a single-blind, placebo- controlled, across-subjects, single-dose escalation design at doses up to 192 mg in adult ADHD subjects. Of 16 subjects at each dose level, twel ve will be randomly assigned to receive betahistine (48, 96, 192 mg) and four to placebo. Safety measures, including vital signs, electrocardiogram, peak respiratory flow, and clinical laboratory tests will be performed during the trial and clinical advers e events will be recorded. Safety data from each dose will be evaluated before progression to the next dose level. Prediction: Betahistine at all doses will be well tolerated with a frequency of adverse events not different from placebo. Specific Aim 2: De termine the single-dose pharmacokinetics and relative dose proportionality of betahistine hydrochloride administered at doses of 48, 96, and 192 mg. Using sampling times determined from preliminary testing at 16 mg single oral dose, we will evalulate a 24 hour sampling period after study drug administration. Betahistine and it's predominant metabolite (2-pyridylacetic acid) concentrations will be determined and AUC, Cmax, Tmax, and half-life will be calculated. AUC and Cmax will be examined statistically fo r proportionality with rising dose. Prediction: Betahistine will show linear increases in AUC and Cmax with increasing doses while Tmax and half-life will remain relatively constant. Specific Aim 3: Examine feasibility of betahistine to improve attention a nd reduce impulsivity by evaluating cognitive performance in adult ADHD subjects following betahistine at doses up to 192 mg relative to placebo. Subjects will be assessed at baseline and at 2 and 4 hours after a single betahistine dose for attention using a Continuous Performance Test and Stroop task, and assessed for impulsivity using the stop-signal reaction time (SSRT). The results of cognitive assessments will be compared statistically as a function of time and betahistine dose. Prediction: Betahistine will demonstrate dose-dependent increases in attention and faster stop-signal reaction times (SSRT) relative to placebo, indicating improved attention and greater capacity to inhibit response.Project Narrative: Attention-deficit, hyperactivity disorder (A DHD) is the most prevalent behavioral disorder of childhood (5-10%), which persists into adult life, causing significant morbidity in terms of academic and vocational outcomes as well as psychosocial impact on families. The financial cost of illness is est imated at 12-17K per annum with a total cost to the health care system of 42 billion. First-line treatment with psychostimulants, while effective, exhibit significant side-effects, abuse potential, and can aggravate movement disorder (i.e. Tourette Syndr ome). A novel approach to the treatment of ADHD through selective cortical histamine activation is now feasible using betahistine. Betahistine at low dose has been used to treat Meniere's Syndrome (vertigo) for over thirty-five years, but only recently has it been demonstrated that higher doses can improve vigilance in normal volunteers. This Phase 1 SBIR proposal will determine the safety, tolerability, and pharmacokinetics of higher doses of betahistine and characterize dose-response for improving attenti on and impulsivity in young adults with ADHD.

Principal Investigator:

Charles H. Pierce
RMOCONNOR@P2DINC.COM

Business Contact:

Frank Xemlan
rmooconnor@p2dinc.com
Small Business Information at Submission:

P2D, INC.
P2D, INC. 3130 HIGHLAND AVE, 3RD FL CINCINNATI, OH 45219

EIN/Tax ID: 202224724
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No